zepbound tirzepatide injection Zepbound® Vial Zepbound beats Wegovy for weight

Our master nurse injectors understand this concern, so heres how we make your journey easier, more efficient, and patient friendly at InjectCo: *In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) and Zepbound (15 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)

In trials, retatrutide produced larger average weight loss (about 24.2% at 48 weeks versus roughly 20.9% for tirzepatide at 72 weeks)

MYC rules: leading glutamine metabolism toward a distinct cancer cell phenotype

Tissue repair

A new 4 mg maintenance-dose arm is under evaluation and may define the post-titration strategy once primary weight loss is achieved